CN101181269A - 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 - Google Patents

法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Download PDF

Info

Publication number
CN101181269A
CN101181269A CNA2007101860344A CN200710186034A CN101181269A CN 101181269 A CN101181269 A CN 101181269A CN A2007101860344 A CNA2007101860344 A CN A2007101860344A CN 200710186034 A CN200710186034 A CN 200710186034A CN 101181269 A CN101181269 A CN 101181269A
Authority
CN
China
Prior art keywords
application
amount
fpt inhibitor
inhibitor
administered twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101860344A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·库特勒尔
M·L·迈尔斯
C·鲍姆
S·L·扎克诺恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101181269A publication Critical patent/CN101181269A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007101860344A 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 Pending CN101181269A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334411 2001-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028239202A Division CN1617755A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Publications (1)

Publication Number Publication Date
CN101181269A true CN101181269A (zh) 2008-05-21

Family

ID=23307076

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101860344A Pending CN101181269A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CNA028239202A Pending CN1617755A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028239202A Pending CN1617755A (zh) 2001-11-30 2002-11-25 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN101181269A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
KR20250102088A (ko) 2022-11-09 2025-07-04 메르크 파텐트 게엠베하 선천성 항종양 면역을 유발시키기 위한 면역-자극제로서 Toll-유사 수용체 7 효현제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
BR0214564A (pt) 2004-11-09
EP1448268A2 (en) 2004-08-25
WO2003047697A3 (en) 2003-10-30
US20030185831A1 (en) 2003-10-02
NO20042730L (no) 2004-06-29
MXPA04005207A (es) 2004-08-19
HUP0402401A2 (hu) 2005-03-29
CA2468839A1 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17
CN1617755A (zh) 2005-05-18
ZA200403737B (en) 2005-05-23
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
Mayer et al. Chemotherapy for metastatic breast cancer
EP4506004A1 (en) Pharmaceutical composition, use thereof, and method for treating cancer
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
JP2003533485A5 (https=)
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
CN101181269A (zh) 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
Ray-Coquard et al. A role for maintenance therapy in managing sarcoma
JP2005511663A5 (https=)
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
EP1711188B1 (en) Anti-cancer therapies
WO2007140299A2 (en) Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
Duenas-Gonzalez et al. Pharmacotherapy options for locally advanced and advanced cervical cancer
MXPA06013902A (es) Procedimiento para tratar el crecimiento de celulas anormal.
JP2022543712A (ja) 組成物及びがん治療用医薬品の調製におけるその応用
MX2007013830A (es) Terapia de combinacion.
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
Ricart et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
HK40059772A (en) Composition and application thereof in preparation of medicament for treating cancer
Reyderman et al. Eribulin and cytochrome P450 effectors: in vitro studies and population pharmacokinetic–pharmacodynamic analysis
IL288591B1 (en) Tak-441 for use in cancer treatment in combination with other cancer therapies
Board et al. COI
HK1078475A (en) Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080521